Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
H.C. Wainwright trimmed its 12-month price target on Summit Therapeutics (NASDAQ: SMMT) to $30 from $40 while keeping a Buy rating, attributing the reduction to uncertainty over the timing of overall survival data from China trials. The firm raised its discount rate and flagged that the stock's upside this year depends on definitive front-line over…
H.C. Wainwright raised its 12-month price target for ORIC Pharmaceuticals to $25 from $23 and kept a Buy rating, citing an active slate of clinical readouts in 2026 that could shape registrational plans. The company's shares have rallied sharply year-to-date and over the past week, while analysts point to upcoming ORIC-944 dose optimization data an…
H.C. Wainwright reduced its 12-month price target for Corcept Therapeutics to $60 from $67 while retaining a Buy rating, citing a more cautious pricing outlook for the Korlym franchise. The action follows fourth-quarter 2025 results that missed revenue and adjusted EPS expectations, operational disruptions tied to a specialty pharmacy transition, a…
H.C. Wainwright reduced its price target on BioMarin Pharmaceutical to $55 from $60 and kept a Neutral rating, citing increased competitive pressure on the company's VOXZOGO treatment. The stock trades at $62.62, and analysts' targets span $60 to $120. Financial results for the fourth quarter of 2025 were mixed, with EPS missing forecasts but reven…
H.C. Wainwright increased its price target on Apellis Pharmaceuticals to $48 from $45 while keeping a Buy rating, citing a more favorable outlook for Syfovre driven by improving affordability in the geographic atrophy market. The firm raised peak sales estimates to $1 billion and revised near-term revenue expectations, reflecting stronger momentum …
H.C. Wainwright cut its price target on Day One Biopharmaceuticals to $22 from $25 but left its Buy rating intact. The biotech, valued at $1.23 billion, posted strong commercial performance for OJEMDA in 2025 and reiterated 2026 revenue guidance as it progresses a pipeline of antibody-drug conjugates with data and enrollment milestones expected thr…
H.C. Wainwright increased its price target for Alpha Tau Medical Ltd. to $12.00 from $9.00 while keeping a Buy rating, after Japan's Ministry of Health, Labour and Welfare approved Alpha DaRT for certain head and neck cancers. The approval triggers a required post-market surveillance study in Japan and opens reimbursement and clinical discussions w…
Switzerland's Federal Council has approved a one-off payment of 50,000 Swiss francs ($56,000) to severely injured survivors and families of those who died in the New Year bar fire at Crans-Montana. The measure, described as a 'solidarity contribution,' is intended to deliver rapid financial relief, and the government will also fund mediation effort…
Jefferies upgraded Enphase Energy to Buy from Hold and raised its price target to $57 from $42, pointing to improving demand and margin clarity after a projected 2026 volume trough. The firm highlighted growing financing confidence, a commercial ramp of the IQ9 platform, and upcoming fifth-generation storage hardware in H2 2026 as key drivers. Mult…
J.P. Morgan placed FinecoBank Banca Fineco SpA on Positive Catalyst Watch ahead of the bank's inaugural Capital Markets Day on March 4, raising its December 2027 price target to €27 from €26.40 and keeping an overweight rating. The bank expects management to disclose above-consensus growth targets for 2026-29 that could lift earnings-per-share esti…
UBS analyst Matthew Mish set out a tail-risk scenario in which a rapid, severe AI disruption would materially worsen defaults and tighten credit across U.S. high-yield, leveraged loan and private credit markets. The bank quantified potential default rates, estimated losses and drawn exposures, and highlighted concentrations and stress signals that …
In its annual budget, South Africa's National Treasury said it will propose a "principles-led" fiscal anchor at the mid-term budget later this year, prioritizing a guideline-based framework rather than a fixed numerical target to shore up public finances amid a steep rise in debt and modest growth projections.
Futures tied to Canada’s primary equity benchmark rose modestly on Wednesday as investors positioned ahead of Nvidia’s earnings. The S&P/TSX 60 futures gained 8 points, while the prior session saw the S&P/TSX composite reach 33,970.38. Strength in materials and mixed corporate results in Canada and the U.S., plus developments on tariffs and energy …
Shares of Lithium Americas (LAC) and Albemarle (ALB) climbed after Zimbabwe announced an immediate suspension of lithium concentrate and raw mineral exports. The ban will stay in force until mining companies meet government requirements to build processing capacity inside Zimbabwe, accelerating an earlier plan to end concentrate exports by 2027. SQ…
Leerink Partners raised its price target on Vaxcyte to $82 from $77 and kept an Outperform rating after the company reported fourth-quarter 2025 results and said it will resume development of VAX-A1, a Group A Streptococcus vaccine candidate, advancing it into a Phase 1 adult trial in 2026. Vaxcyte has strengthened its balance sheet through recent …
Leerink Partners trimmed its price objective on Tectonic Therapeutics Inc. (NASDAQ: TECX) to $60 from $69 while retaining an Outperform recommendation. The revision follows adjustments in the firm’s discounted cash flow model that reduced the likelihood of success for TX45 and raised the probability for TX2100. Wall Street consensus remains constru…
MoffettNathanson increased its 12-month price target for Apple to $270 from $241 while leaving its rating on the shares unchanged at Neutral. The firm cited quickly evolving dynamics around memory pricing and tariffs, a reassessment of Apple’s stance in Greater China, and positive earnings revisions following a strong December quarter. The upgrade …
TD Cowen downgraded Workday to Hold from Buy and reduced its price target to $155, citing fourth-quarter deal slippage and weaker growth prospects. The stock is trading near its 52-week low, and a string of analyst revisions underscores concern about revenue momentum, margin expansion and the timeline for Workday's AI rollout to stabilize growth.
Raymond James trimmed its 12-month price target on MercadoLibre to $2,500 from $2,775 while retaining a Strong Buy rating after the company reported results that mixed outperformance in volumes and payments with weaker-than-expected profitability. MercadoLibre delivered stronger gross merchandise volume and total payment volume than Street forecast…
Raymond Debbane, a member of Lexicon Pharmaceuticals' board, acquired 100,000 common shares on February 23, 2026, investing $147,000. The transaction occurred as the company concluded a major equity raise and received FDA clearance to move its investigational therapy pilavapadin into Phase 3 testing for diabetic peripheral neuropathic pain.
Deutsche Bank lowered its recommendation on Beiersdorf AG from buy to hold, saying the stock's year-to-date rally has largely priced in the upside. The bank kept its target at €105, below the recent close of €109.70, and highlighted valuation and potential headwinds in the tesa adhesives division tied to memory shortages in consumer electronics.
First Solar's shares fell sharply in premarket trading after the company projected 2026 net sales below analyst expectations, citing uncertainty in the U.S. policy environment, permitting delays and tariff pressures. Management outlined a plan to open a U.S. finishing line in South Carolina to alleviate supply constraints for the Series 6 module an…
Lumen Technologies said it has finished a corporate turnaround and unveiled a multi-year plan focused on expanding its fiber network, growing enterprise revenue, and improving margins. The announcement at its 2026 Investor Day helped lift the stock by 9% on Wednesday morning as the company mapped a path to larger adjusted EBITDA margins, broader pr…
BofA Securities downgraded Molson Coors from Neutral to Underperform and reduced its price target to $42 from $50 after the brewer’s Q4 2025 results and a presentation at CAGNY. The bank kept a roughly 9x P/E multiple on 2027 estimates but highlighted a weaker fiscal 2026 outlook and limited visibility on volumes, increasing downside risk to earnin…
BofA Securities increased its price target for Dycom Industries to $475 from $365 while retaining a Buy rating, tying the new target to roughly 17 times Dycom's fiscal 2027 estimated EV/EBITDA. The bank highlighted growth drivers including fiber-to-the-home deployments, a sizable BEAD program total addressable market, and data center-related electr…
